Citations

Clear

3042 citation(s) found for "Kumar, S".

Forecasting Alcohol‐Related Liver Disease Mortality Trends in Younger Populations Using Advanced Time‐Series Models: A 1999–2030 Analysis
Ali, Hassam , Blaney, Hanna , Dahiya, Dushyant Singh , Gangwani, Manesh Kumar , Patel, Pratik , Jaber, Fouad , Satapathy, Sanjaya K. , Dahiya, Dushyant Singh , Sathapathy, Sanjaya , Jahagirdar, Vinay , Hayat, Umar , Simonetto, Douglas A.

Mayo Clinic

JGH Open | December 4, 2024 | Volume: 8 | Issue: 12 | Pages: No page available

10.1002/jgh3.70057 | PMID 39634629 Get It

ABSTRACTObjectiveAlcohol‐related liver disease (ALD) has emerged as a significant public health concern, particularly among younger populations. ALD remains the leading cause of alcohol‐attributable deaths. This study aims to forecast ALD mortality trends up to 2030, focusing on individuals under 55 years.MethodsWe utilized data from the CDC WONDER database (1999–2022) to examine ALD‐related deaths, identified by ICD‐10 codes (K70.0–K70.9). Crude mortality rates (CMRs) per 100 000 were analyzed and temporal trends were assessed using annual and average annual percent changes (APC/AAPC) with empirical quantile confidence intervals. An Autoregressive Integrated Moving Average (ARIMA) model was employed to project mortality rates until 2030, validated through time series cross‐validation.ResultsFrom 1999 to 2022, there were 181 862 ALD‐related deaths among individuals under 55, with mortality rates increasing from 3.9 per 100 000 in 1999 to 9.7 per 100 000 in 2022 (AAPC 4.66%, 95% CI: 3.90%–5.86%). Projections suggest rates will continue to rise, reaching 14.4 per 100 000 by 2030. From 1999 to 2022, the 25–34 age group experienced the highest increase, with an AAPC of 10.27% (95% CI: 9.19%–11.35%), while the 35–44 and 45–54 age groups showed more moderate increases, with AAPCs of 5.03% and 4.38%, respectively. Projections indicate an AAPC of 3.86% for ages 25–34, 3.90% for ages 35–44, and 6.17% for ages 45–54 by 2030.ConclusionForecasts indicate a continued rise in ALD mortality among individuals under 55, necessitating immediate public health strategies to mitigate this trend.
Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM
Kumar, Shaji , Cohen, Inbar , Shimony, Shai, Dingli, David , Muchtar, Eli , Kapoor, Prashant , Hogan, W. Michael, Hayman, Suzanne, Kourelis, Taxiarchis , Warsame, Rahma , Vaxman, Iuliana , Kumar, Shaji K , Muchtar, E , Kapoor, Prashant , Leung, Nelson , Gonsalves, Wilson , Kourelis, Taxiarchis , Gertz, Morie A , Dingli, David , Vaxman, Iuliana , Shimony, Shai, Dispenzieri, Angela , Buadi, Francis K. , Hogan, William, Leung, Nelson , Gonsalves, Wilson I. , Gertz, Morie A.

Mayo Clinic

British Journal of Haematology | November 29, 2024 | Volume: 206 | Issue: 2 | Pages: 607-614

10.1111/bjh.19936 | PMID 39613336 Get It

Summary In 2014, the International Myeloma Working Group (IMWG) updated the criteria for diagnosing myeloma and added three additional criteria to the traditional Calcium elevation, Renal impairment, Anemia, Bone disease (CRAB) criteria, called the Sixty % marrow plama cells, Light chain ratio >60, Mri demonstates lytic lesions (SLiM) criteria (clonal bone marrow plasma cells ≥60%, involved to uninvolved free light chain ratio (FLCr) ≥100 and >1 focal lesion on magnetic resonance imaging (MRI)). We report on the outcomes of 30 patients who underwent autologous stem cell transplantation (ASCT) where therapy was initiated solely based on SLiM criteria and compared them to a matched cohort of 60 patients whose myeloma‐defining event was CRAB. The SLiM cohort had a shorter median time to neutrophil (15 vs. 16 days, p = 0.049) and platelet (15 vs. 17 days, p = 0.0004) engraftment. The 36‐month overall survival (OS) was 100% in the SLiM group and 93.27% in the control group (95% CI 83.06%–97.42%), with a trend towards longer OS in the SLiM cohort ( p = 0.065). The 36‐month progression‐free survival (PFS) was 91.61% in the SLiM (95% CI 69.93%–97.87%) and 65.95% in the control group (95% CI 52.31%–76.53%). There was no difference in the PFS between the cohorts ( p = 0.414). ASCT is efficacious and safe in MM patients transplanted only due to SLIM criteria. Early intervention in this asymptomatic cohort did not appear to result in deeper responses or better PFS compared to outcomes in symptomatic patients.
Increased occurrence of malignancy before and after chemoradiation for anal squamous cell carcinoma: a multi-institutional analysis
Kumar, Ritesh , Hallemeier, Chris L., Lu, Shou‐En , Hristidis, Vasilis , Jethwa, Krishan R. , Baclay, J.R.M. , Chakrani, Z., Haddock, Michael G. , Toesca, Diego A.S. , Pollom, Erqi L., Jethwa, Krishan , Baclay, J Richelcyn M , Manne, Veeraswamy , Chakrani, Zakaria , Toesca, Diego Augusto Santos, Pollom, Erqi Liu , Wu, Abraham J , Sandhyavenu, Harigopal , Romesser, Paul B , Jabbour, Salma K , Chang, Daniel T. , Hathout, Lara , Sandhyavenu, Harigopal , Romesser, Paul B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 27, 2024 | Volume: 117 | Issue: 4 | Pages: 772-780

10.1093/jnci/djae309 | PMID 39626307 Get It

Abstract Background Anal squamous cell carcinoma is a rare cancer with increased occurrence of multiple cancers before and after the anal squamous cell carcinoma diagnosis. However, there are limited data on this aspect. This multi-institutional analysis aimed to define the occurrence of malignancies before and after anal squamous cell carcinoma, time trends, and impact on survival and to identify prognostic factors. Methods Initial primary malignancy was defined as a malignancy occurring before the anal squamous cell carcinoma. Second primary malignancy was defined as a distinct primary cancer that developed after anal squamous cell carcinoma diagnosis. Retrospective multi-institutional chart review was done. Progression-free survival (PFS), overall survival, and prognostic factors were evaluated. Results A total of 647 patients with anal squamous cell carcinoma treated with curative intent were analyzed. Median age was 61.2 years with 72% as females. Of these, 150 (23.3%) patients had multiple malignancies with initial primary malignancy in 16% and second primary malignancy in 8%. Patients without prior cancer had better 5-year PFS (81.2% vs 67.2%, P = .011) and overall survival (81% vs 69%, P = .008) compared with those with prior cancer. Second primary malignancies had a statistically significant adverse impact on PFS (hazard ratio [HR] = 4.22) and overall survival (HR = 3.56). Females had better 5-year PFS (82% vs 70%, P = .016) as compared with males. The median time interval for developing anal squamous cell carcinoma (as second primary malignancy) after initial primary malignancy was 9.32 years. Conclusions Anal squamous cell carcinoma patients have an increased risk of multiple malignancies. These patients who have prior cancers have inferior outcomes. Second primary malignancy is a poor prognostic factor in patients with anal cancer. Second primary malignancy can develop years after treatment of primary anal squamous cell carcinoma.
Surgical Trends in Chronic Pancreatitis From 2014 to 2021
Turunen, Arto , Garg, Sushil Kumar , Turunen, Andrew

Mayo Clinic

Pancreas | November 26, 2024 | Volume: 54 | Issue: 4 | Pages: e310-e316

10.1097/mpa.0000000000002438 | PMID 39591530 Get It

Objectives: We analyzed annual surgical trends for benign chronic pancreatitis (CP), studying specifically mortality, morbidity, and pancreatic fistula rates. We also aimed to identify predictors of pancreatic fistula formation. Materials and Methods: For this analysis, we used data from the American College of Surgeons National Surgical Quality Improvement Program from 2014 to 2021. The study included patients who underwent surgery for benign CP. Data collected included patient demographics, preoperative variables, and postoperative outcomes. Data were analyzed with univariate and multivariate analyses, with significance defined as P ≤ 0.05. Results: Over the study period, the number of pancreatic surgical procedures increased by 49.3%, although surgery specifically for CP declined by 31.7%. The rate of pancreatic fistula formation decreased 44.9%, and mortality decreased 31.9%. Significant predictors of a pancreatic fistula included no diabetes, preoperative sepsis, soft texture of the pancreatic gland, and greater patient weight. Conclusion: Surgery for benign CP decreased substantially despite the established efficacy of surgical intervention for long-term pain management. The concurrent decline in mortality and rates of pancreatic fistula formation suggest advances over the study years in surgical and postoperative care.
Current Stroke Solutions Using Artificial Intelligence: A Review of the Literature
Al‐Janabi, Omar , Refaei, Amro El, Elgazzar, Tasnim , Mahmood, Yamama M., Bakir, Danah, Gajjar, Aryan, Alateya, Aysha, Jha, Saroj Kumar , Ghozy, Sherief , Kallmes, David F. , Brinjikji, Waleed , Al-Janabi, Omar M , Ghozy, Sherief , Gajjar, Aryan

Mayo Clinic

Brain Sciences | November 26, 2024 | Volume: 14 | Issue: 12 | Pages: 1182

10.3390/brainsci14121182 | PMID 39766381 Get It

Introduction: In recent years, artificial intelligence (AI) has emerged as a transformative tool for enhancing stroke diagnosis, aiding treatment decision making, and improving overall patient care. Leading AI-driven platforms such as RapidAI, Brainomix®, and Viz.ai have been developed to assist healthcare professionals in the swift and accurate assessment of stroke patients. Methods: Following the PRISMA guidelines, a comprehensive systematic review was conducted using PubMed, Embase, Web of Science, and Scopus. Characteristic descriptive measures were gathered as appropriate from all included studies, including the sensitivity, specificity, accuracy, and comparison of the available tools. Results: A total of 31 studies were included, of which 29 studies focused on detecting acute ischemic stroke (AIS) or large vessel occlusions (LVOs), and 2 studies focused on hemorrhagic strokes. The four main tools used were Viz.ai, RapidAI, Brainomix®, and deep learning modules. Conclusions: AI tools in the treatment of stroke have demonstrated usefulness for diagnosing different stroke types, providing high levels of accuracy and helping to make quicker and more precise clinical judgments.
Contemporary Outcomes of TAVR Using a Balloon-Expandable Valve in Patients With Severe Mitral Stenosis: Insights From the Transcatheter Valve Therapies Registry
Ahmad, Imran, Flaherty, James D. , Nagaraja, Vinayak , Huded, Chetan , Reed, Grant W. , Puri, Rishi , Rassi, Andrew N., Goel, Sachin S. , Jneid, Hani , Zahr, Firas , Krishnaswamy, Amar , Kumar, Anirudh , Flaherty, James D , Nagaraja, Vinayak , Huded, Chetan P , Reed, Grant W , Puri, Rishi , Goel, Sachin S , Jneid, Hani , McCabe, James M , Guerrero, Mayra E , Zahr, Firas , Krishnaswamy, Amar , Kapadia, Samir , Ahmad, Imran N., Guerrero, Mayra , Kapadia, Samir

Mayo Clinic

Circulation: Cardiovascular Interventions | November 22, 2024 | Volume: 17 | Issue: 12 | Pages: No page available

10.1161/circinterventions.124.014216 | PMID 39575576 Get It

BACKGROUND: While initial data for transcatheter aortic valve replacement (TAVR) in aortic stenosis patients with mitral stenosis (MS) suggested a poor short-term prognosis, outcomes for contemporary balloon-expandable valves remain unknown. The aim of this retrospective multicenter registry study was to compare the potential impact of MS on TAVR outcomes with balloon-expandable valves. METHODS: Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry and Centers for Medicare & Medicaid Services claims data were used to obtain a cohort of 327 925 patients who underwent TAVR with current balloon-expandable valves (SAPIEN 3, SAPIEN 3 Ultra, or SAPIEN 3 Ultra Resilia) between June 2015 and December 2022 across 791 sites. Severe MS (defined as >10 mm Hg mean gradient or <1.5 cm 2 area) was compared with mild or less MS (defined as <5 mm Hg mean gradient and >2 cm 2 area) using propensity matching to minimize confounding variables. RESULTS: Patients with severe MS (n=8500; 2.6%) had a higher number of comorbid conditions, Society of Thoracic Surgeons risk scores, and were more often women than patients with mild or less MS at the time of index TAVR. While patients with severe MS had worse outcomes at 30 days, when propensity-matched, patients exhibited similar 30-day rates of death (3.2% versus 3.0%), stroke (2.4% versus 2.2%), major vascular complications (1.6% versus 1.6%), device implant success (98.9% versus 99.2%), and new dialysis (0.7% versus 0.5%), with higher rates of pacemaker implantation (11.3% versus 9.4%; P <0.001). By 1 year, there was no difference in the change in the KCCQ (Kansas City Cardiomyopathy Questionnaire) overall score from baseline to 1 year (30.7±27.0 versus 31.9±27.0; P =0.07). By 3 years, an increase in the mortality rate (45.1% versus 40.9%; P <0.001) of patients with severe MS was observed. CONCLUSIONS: MS in isolation is not associated with worsened short-term outcomes among patients undergoing contemporary TAVR with balloon-expandable valves.
QUEST-AI: A System for Question Generation, Verification, and Refinement using AI for USMLE-Style Exams
Bedi, Suhana , Morse, Keith , Kumar, A., Jindal, Jenelle , Davenport, Conor , Fleming, Scott L. , Chiang, Chia‐Chun , Patel, Birju , Yamaguchi, Craig , Shah, Nigam H.

Mayo Clinic

Biocomputing 2025 | November 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: 54-69

10.1142/9789819807024_0005 | PMID 39670361 Get It

Safety and Efficacy of Seladelpar in Treatment of Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
Raja, Adarsh , Rahman, Hafsah Alim Ur , Kumar, Mukesh , Kumar, Sumet, Sohaib Asghar, Muhammad, Ahmed, Muhammad , Raja, Sandesh , Asghar, Muhammad Sohaib , Kumar, Sumet

Mayo Clinic

American Journal of Therapeutics | November 21, 2024 | Volume: 32 | Issue: 2 | Pages: e194-e197

10.1097/mjt.0000000000001829 | PMID 39570808 Get It

Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis
Paramasivan, Naveen Kumar , Karsten, Carley , Zahid, Anza , Kherbek, Haidara , Ζεκερίδου, Αναστασία , Sista, Sri Raghav, Dasari, Surendra , Mangioris, Georgios , Mills, John R. , Pittock, Sean J, Dubey, Divyanshu , Pittock, Sean J. , Dubey, Divyanshu , Pittock, S J , Masoud, Majed, Kherbek, Haidara , Zekeridou, Anastasia , Knight, Andrew M, McKeon, Andrew , Dubey, Divyanshu , Dubey, Divyanshu , Paramasivan, Naveen K , Masoud, Majed, Knight, Andrew M., McKeon, Andrew

Mayo Clinic

Annals of Clinical and Translational Neurology | November 18, 2024 | Volume: 12 | Issue: 2 | Pages: 280-290

10.1002/acn3.52254 | PMID 39556523 Get It

AbstractObjectiveTo describe the phenotypes, oncological associations, biomarker profiles, and outcomes across different age groups in patients with ANNA1 (anti‐Hu) autoimmunity.MethodsA retrospective review of patients with ANNA1‐IgG in serum/CSF between January 1, 2001, and December 31,2019 was performed. Patients were classified into three groups based on the age of symptom onset. Phage immunoprecipitation sequencing (PhIP‐Seq) and neurofilament light chain (NfL) measurements were done in patient sera/CSF with archived samples.ResultsOf 122 patients, 81 (66%), 20 (16%), and 21 (17%) patients belonged to older adults, young adults, and pediatric groups, respectively. Lung cancer and neuromuscular presentations were more common in older adults (p < 0.001), while limbic encephalitis and neuroblastoma were more common in pediatric patients (p < 0.005). Most young adults (75%) did not have cancer identified. Proportions of patients with a favorable response to immunotherapy were 20%, 30%, and 52% among older adults, young adults, and pediatric groups, respectively. PhIP‐Seq demonstrated significant enrichment for ELAVL4 peptides especially for amino acids 240–289, in the majority of samples evaluated (36/67, 54%). ZIC and SOX2 peptides were significantly enriched in those with central nervous system presentations. Serum NfL levels were elevated in patients with cancer and those with poor long‐term outcomes.InterpretationYoung adults with ANNA1 autoimmunity phenotypically resembled older adults but rarely had an underlying cancer. Pediatric patients frequently presented with limbic encephalitis and neuroblastoma and often responded favorably to immunotherapy. Distinct antigenic signatures may underlie differences in clinical presentations. Serum NfL levels may be a biomarker of poor long‐term outcomes in ANNA1 autoimmunity.
Abstract Sa507: Neurological prognostication by gray-white matter ratio on dual-energy brain computed tomography for extracorpeal cardiopulmonary resuscitation patients
Li, Boyangzi , Bentho, Oladi , Fridman, Renee, Mello, Gregory, Tandon, Rishabh , Gutiérrez, Alejandra , Yannopoulos, Demetris , Elliott, Andrea , Bartos, Jason A. , Dahiya, Garima , SINGH, RAHUL KUMAR

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.sa507 Get It

Introduction: Gray-white matter ratio (GWR) on non-contrast head computed tomography (HCT) is a helpful tool in neuro-prognostication in post-cardiac arrest patients. Its usage is unclear for those with angiography due to residual contrast. Hypothesis: GWR remains valid for neuro-prognostication in comatose patients undergoing extracorporeal cardiopulmonary resuscitation (ECPR) followed by coronary angiography (CAG) after out-hospital cardiac arrest (OHCA). Methods: We performed a retrospective study of comatose OHCA adults post ECPR and CAG at University of Minnesota from January to June 2022 with dual energy HCT within 12 hours. GWR was measured at basal ganglia, centrum semiovale, and high convexity levels. Gray matter areas of interest included caudate nucleus, putamen, thalamus, and medial cortex. The white matter areas of interest included the genu of the corpus callosum, posterior limb of the internal capsule, and medial white matter. Circular regions of interest (ROI, 10-15 mm 2 ) were placed bilaterally in corresponding areas to record the average attenuation in Hounsfield unit (HU). The basal ganglia, cerebrum, and overall GWRs were calculated as the ratio of average HU between the gray and white matter ROIs within the area. Primary outcome was inpatient death, further categorized by the primary cause being neurological or not. Logistic regression followed by receiver operating characteristic (ROC) curves was used to validate GWR in predicting death. All data analysis was performed by StataCorp Software (STATA 14). Result: 25 patients were included in the study. 18 (72%) were male with a median age of 60 (interquartile range (IQR): 45-67). The initial HCT was obtained at 2.08 hours (median, IQR: 1.37–2.43) post ECPR cannulation. 7 (28%) patients died from brain death or herniation and 15 (60%) died from non-neurological causes. None had intracranial bleeding. 1 patient had unilateral hypodensity on initial HCT, suggesting an acute embolic infarct. Patients who died had lower GWRs on initial HCT (Figure 1). ROC regression showed all GWRs demonstrated good prognostic performance on inpatient death with area under the curve (AUC) of 0.6970 (basal ganglia), 0.8485 (cerebrum), and 0.7576 (overall) (Figure 2). Conclusions: GWR in early HCT has prognostic value in predicting neurological outcomes despite residual contrast. It may be used as a risk stratification tool for comatose OHCA patients undergoing ECPR and angiography.